Photo Gallery



News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • OCTOBER 2020 Issue has been successfully launched on 1 October 2020.



Monika Chauhan*, Anshul Jain and Satyaveer Singh, Kuldeep Chaurasiya


The purpose of the present study was to develop sustained release tablets of Miglitol, an oral alpha-glucosidase inhibitor for use in the management of non-insulin-dependent diabetes mellitus (NIDDM), an anti-diabetic drug which are designed for better management of diabetes mellitus to minimize side effects, to improve patient compliance and preventing the fluctuation of therapeutic concentration of the drug in the body.The Miglitol sustained release tablets (F1 – F10) were prepared by direct compression method using HPMC K4,K15,K100 polymers in different ratios.. Granules were performed by Preformulation studies. The Miglitol sustained release tablets were evaluated for hardness, friability, weight variation, drug content and In-vitro dissolution study. The Miglitol sustained release tablets showed drug release from 18.42 to 96,6% of drug at the end of 12th hr by in-vitro dissolution study. The formulation F8 was selected as an optimized formulation because it gives the best result in terms of drug release in sustained release manner. The kinetic release treatment showed that the release of drug follows zero order kinetic (R2 value as 0.997), korsemeyer equation gave value of (R2= 0.879) which was close to one indicating that the drug was released by zero order kinetic and Short term stability studies indicated that there is no appreciable changes in the drug content and in vitro drug release rates of optimized formulation F8.

Keywords: Miglitol, HPMC K4, K15, K100, Direct compression Method, Sustained Release.

[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More